Reduction of N-acetyl aspartate (NAA) in association with relapse in early-stage psychosis: a 7-Tesla MRS study.
Marina MihaljevicYu-Ho ChangAshley M WitmerJennifer M CoughlinDavid J SchretlenPeter B BarkerKun YangAkira SawaPublished in: Schizophrenia (Heidelberg, Germany) (2024)
Understanding the biological underpinning of relapse could improve the outcomes of patients with psychosis. Relapse is elicited by multiple reasons/triggers, but the consequence frequently accompanies deteriorations of brain function, leading to poor prognosis. Structural brain imaging studies have recently been pioneered to address this question, but a lack of molecular investigations is a knowledge gap. Following a criterion used for recent publications by others, we defined the experiences of relapse by hospitalization(s) due to psychotic exacerbation. We hypothesized that relapse-associated molecules might be underscored from the neurometabolites whose levels have been different between overall patients with early-stage psychosis and healthy subjects in our previous report. In the present study, we observed a significant decrease in the levels of N-acetyl aspartate in the anterior cingulate cortex and thalamus in patients who experienced relapse compared to patients who did not. Altogether, decreased N-acetyl aspartate levels may indicate relapse-associated deterioration of neuronal networks in patients.
Keyphrases
- early stage
- free survival
- poor prognosis
- long non coding rna
- functional connectivity
- resting state
- end stage renal disease
- healthcare
- white matter
- magnetic resonance
- chronic obstructive pulmonary disease
- newly diagnosed
- metabolic syndrome
- chronic kidney disease
- mental health
- ejection fraction
- type diabetes
- prognostic factors
- blood brain barrier
- sentinel lymph node
- bipolar disorder
- cerebral ischemia
- mass spectrometry
- photodynamic therapy
- weight loss
- intensive care unit
- subarachnoid hemorrhage
- single molecule
- locally advanced
- case control